[1]
|
Döhner, H., Weisdorf, D.J. and Bloomfield, C.D. (2015) Acute Myeloid Leukemia. The New England Journal of Medicine, 373, 1136-1152. https://doi.org/10.1056/NEJMra1406184
|
[2]
|
Evison, B.J., Sleebs, B.E., Watson, K.G., et al. (2016) Mitoxantrone, More than Just Another Topoisomerase II Poison. Medicinal Research Reviews, 36, 248-299.
|
[3]
|
Dimarco, A., Gaetani, M., Orezzi, P., et al. (1964) “Daunomycin”, a New Antibiotic of the Rhodomycin Group. Nature, 201, 706-707. https://doi.org/10.1038/201706a0
|
[4]
|
Tan, C., Tasaka, H., Yu, K.P., et al. (1967) Daunomycin, an Antitumor Antibiotic, in the Treatment of Neoplastic Disease. Clinical Evaluation with Special Reference to Childhood Leukemia. Cancer, 20, 333-353. https://doi.org/10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K
|
[5]
|
Arcamone, F., Cassinelli, G., et al. (1969) Adriamycin, 14-Hydroxydaimomycin, a New Antitumor Antibiotic from S. peucetius var. caesius. Biotechnology and Bioengineering, 11, 1101-1110. https://doi.org/10.1002/bit.260110607
|
[6]
|
Bonadonna, G., Monfardini, S., De Lena, M., et al. (1970) Phase I and Preliminary Phase II Evaluation of Adriamycin (NSC 123127). Cancer Research, 30, 2572-2582.
|
[7]
|
Bonadonna, G., Monfardini, S., De Lena, M. and Fossati-Bellani, F. (1969) Clinical Evaluation of Adriamycin, a New Antitumour Antibiotic. British Medical Journal, 3, 503-506. https://doi.org/10.1136/bmj.3.5669.503
|
[8]
|
Swain, S.M., Whaley, F.S. and Ewer, M.S. (2003) Congestive Heart Failure in Patients Treated with Doxorubicin: A Retrospective Analysis of Three Trials. Cancer, 97, 2869-2879.
|
[9]
|
Von Hoff, D.D. (1979) Risk Factors for Doxorubicin-lnduced Congestive Heart Failure. Annals of Internal Medicine, 91, 710. https://doi.org/10.7326/0003-4819-91-5-710
|
[10]
|
Murdock, K.C., Child, R.G., Fabio, P.F. and Angier, R.B. (1979) Antitumor Agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. Journal of Medicinal Chemistry, 22, 1024-1030.
|
[11]
|
Morley, J.O. and Furlong, P.J. (2006) Synthesis and Calculated Properties of Some 1,4-Bis(amino)anthracene-9,10-diones. Organic & Biomolecular Chemistry, 4, 4005-4014. https://doi.org/10.1039/b610625k
|
[12]
|
Shenkenberg, T.D. (1986) Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity. Annals of Internal Medicine, 105, 67. https://doi.org/10.7326/0003-4819-105-1-67
|
[13]
|
Faulds, D., Balfour, J.A., Chrisp, P. and Langtry, H.D. (1991) A Review of Its Pharmacodynamic and Pharmacokinetic Properties.
|
[14]
|
Walters, R.S., Kantarjian, H.M., Keating, M.J., et al. (1988) Mitoxantrone and High-Dose Cytosine Arabinoside in Refractory Acute Myelogenous Leukemia. Cancer, 62, 677-682. https://doi.org/10.1002/1097-0142(19880815)62:4<677::AID-CNCR2820620405>3.0.CO;2-B
|
[15]
|
Damiani, R.M., Moura, D.J., Viau, C.M., et al. (2016) Pathways of Cardiac Toxicity: Comparison between Chemotherapeutic Drugs Doxorubicin and Mitoxantrone. Archives of Toxicology, 90, 2063-2076. https://doi.org/10.1007/s00204-016-1759-y
|
[16]
|
Marzola, M., Parma, G., Bonazzi, C., et al. (1996) Salvage Therapy with Ifosfamide and Mitoxantrone in Advanced Ovarian Cancer. Annals of Oncology, 7, 419-421. https://doi.org/10.1093/oxfordjournals.annonc.a010612
|
[17]
|
Marriott, J.J., Miyasaki, J.M., Gronseth, G. and O’Connor, P.W. (2010) Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 74, 1463-1470. https://doi.org/10.1212/WNL.0b013e3181dc1ae0
|
[18]
|
Tannock, I.F., de Wit, R., Berry, W.R., et al. (2004) Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. The New England Journal of Medicine, 351, 1502-1512. https://doi.org/10.1056/NEJMoa040720
|
[19]
|
Wang, L., Cao, J., Li, C., et al. (2022) Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients with Advanced Breast Cancer: A Randomized, Open-Label, Active-Controlled, Single-Center, Phase II Clinical Trial. Investigational New Drugs, 40, 330-339. https://doi.org/10.1007/s10637-021-01182-7
|
[20]
|
Koc, Y., Oyan, B., Kars, A., et al. (2004) A Randomized Trial of Continuous Infusion versus Bolus Mitoxantrone in Combination with Cytarabine in Newly Diagnosed Patients with Acute Myeloblastic Leukemia. Hematological Oncology, 22, 43-53. https://doi.org/10.1002/hon.726
|
[21]
|
Larson, S.M., Campbell, N.P., Huo, D., et al. (2012) High Dose Cytarabine and Mitoxantrone: An Effective Induction Regimen for High-Risk Acute Myeloid Leukemia (AML). Leukemia & Lymphoma, 53, 445-450. https://doi.org/10.3109/10428194.2011.621562
|
[22]
|
Arlin, Z., Case, D.C., Moore, J., et al. (1990) Randomized Multicenter Trial of Cytosine Arabinoside with Mitoxantrone or Daunorubicin in Previously Untreated Adult Patients with Acute Nonlymphocytic Leukemia (ANLL). Lederle Cooperative Group. Leukemia, 4, 177-183.
|
[23]
|
Löwenberg, B., Suciu, S., Archimbaud, E., et al. (1998) Mitoxantrone versus Daunorubicin in Induction-Consolidation Chemotherapy—The Value of Low-Dose Cytarabine for Maintenance of Remission, and an Assessment of Prognostic Factors in Acute Myeloid Leukemia in the Elderly: Final Report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Journal of Clinical Oncology, 16, 872-881. https://doi.org/10.1200/JCO.1998.16.3.872
|
[24]
|
Marconi, G., Talami, A., Abbenante, M.C., et al. (2020) MEC (Mitoxantrone, Etoposide, and Cytarabine) Induces Complete Remission and Is an Effective Bridge to Transplant in Acute Myeloid Leukemia. European Journal of Haematology, 105, 47-55. https://doi.org/10.1111/ejh.13406
|
[25]
|
Mandelli, F., Vignetti, M., Suciu, S., et al. (2009) Daunorubicin versus Mitoxantrone versus Idarubicin as Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10. Journal of Clinical Oncology, 27, 5397-5403. https://doi.org/10.1200/JCO.2008.20.6490
|
[26]
|
Deng, L., Zhang, C., Ying, S., et al. (2021) Effect of Dose Ratio on Mitoxantrone and Daunorubicin in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Lymphoma, Myeloma and Leukemia, 21, e10-e20. https://doi.org/10.1016/j.clml.2020.08.001
|
[27]
|
Shaikh, A.Y., Suryadevara, S., Tripathi, A., et al. (2016) Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia—A Velocity Vector Imaging Analysis. Echocardiography, 33, 1166-1177. https://doi.org/10.1111/echo.13245
|
[28]
|
Anderson, J.E., Kopecky, K.J., Willman, C.L., et al. (2002) Outcome after Induction Chemotherapy for Older Patients with Acute Myeloid Leukemia Is Not Improved with Mitoxantrone and Etoposide Compared to Cytarabine and Daunorubicin: A Southwest Oncology Group Study. Blood, 100, 3869-3876. https://doi.org/10.1182/blood-2001-12-0354
|
[29]
|
Rowe, J.M., Neuberg, D., Friedenberg, W., et al. (2004) A Phase 3 Study of Three Induction Regimens and of Priming with GM-CSF in Older Adults with Acute Myeloid Leukemia: A Trial by the Eastern Cooperative Oncology Group. Blood, 103, 479-485. https://doi.org/10.1182/blood-2003-05-1686
|
[30]
|
Bangham, A.D. and Horne, R.W. (1964) Negative Staining of Phospholipids and Their Structural Modification by Surface-Active Agents as Observed in the Electron Microscope. Journal of Molecular Biology, 8, 660-668. https://doi.org/10.1016/S0022-2836(64)80115-7
|
[31]
|
Bulbake, U., Doppalapudi, S., Kommineni, N. and Khan, W. (2017) Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, 9, 12. https://doi.org/10.3390/pharmaceutics9020012
|
[32]
|
Hashizume, H., Baluk, P., Morikawa, S., et al. (2000) Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness. The American Journal of Pathology, 156, 1363-1380. https://doi.org/10.1016/S0002-9440(10)65006-7
|
[33]
|
Taurin, S., Nehoff, H. and Greish, K. (2012) Anticancer Nanomedicine and Tumor Vascular Permeability; Where Is the Missing Link? Journal of Controlled Release, 164, 265-275. https://doi.org/10.1016/j.jconrel.2012.07.013
|
[34]
|
Safra, T., Muggia, F., Jeffers, S., et al. (2000) Pegylated Liposomal Doxorubicin (Doxil, Reduced Clinical Cardiotoxicity in Patients Reaching or Exceeding Cumulative Doses of 500 mg/m2. Annals of Oncology, 11, 1029-1033. https://doi.org/10.1023/A:1008365716693
|
[35]
|
Lancet, J.E., Uy, G.L., Cortes, J.E., et al. (2018) CPX-351 (Cytarabine and Daunorubicin) Liposome for Injection versus Conventional Cytarabine plus Daunorubicin in Older Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 36, 2684-2692. https://doi.org/10.1200/JCO.2017.77.6112
|
[36]
|
Li, C., Cui, J., Wang, C., et al. (2008) Encapsulation of Mitoxantrone into Pegylated SUVs Enhances Its Antineoplastic Efficacy. European Journal of Pharmaceutics and Biopharmaceutics, 70, 657-665. https://doi.org/10.1016/j.ejpb.2008.05.019
|
[37]
|
Li, C., Zhao, X., Deng, C., et al. (2014) Pegylated Liposomal Mitoxantrone Is More Therapeutically Active than Mitoxantrone in L1210 Ascitic Tumor and Exhibits Dose-Dependent Activity Saturation Effect. International Journal of Pharmaceutics, 460, 165-172. https://doi.org/10.1016/j.ijpharm.2013.10.023
|
[38]
|
Yang, J., Shi, Y., Li, C., et al. (2014) Phase I Clinical Trial of Pegylated Liposomal Mitoxantrone plm60-s: Pharmacokinetics, Toxicity and Preliminary Efficacy. Cancer Chemotherapy and Pharmacology, 74, 637-646. https://doi.org/10.1007/s00280-014-2523-8
|